OKIDS GmbH was founded in 2012 as a subsidiary of the ÖGKJ.
OKIDS GmbH was founded in 2012 as a subsidiary of the ÖGKJ (Austrian Society for Paediatrics and Adolescent Medicine, www.paediatrie.at) and was based on the model of public-private partnership: in the founding phase the Austrian Federal Ministry of Health (BMG), and in the start-up phase until today via partnerships or funding by Pharmig and the industry, the Joint Health Targets from the Pharma Master Agreement and the Austrian Society for Paediatrics and Adolescent Medicine (ÖGKJ).
As a national hub, we offer support for the complete management and organisation of paediatric medicinal product studies within our highly specialised network of paediatric centres at children’s hospitals and universities throughout Austria:
In order to achieve our objective to improve medicinal products appropriately for children, OKIDS operates a children’s research network at six locations in which experienced children’s hospitals and universities throughout Austria (Vienna, Graz, Salzburg, Linz and Innsbruck) have come together to jointly conduct medicinal product studies in children and adolescents.
In addition, we are also strongly involved at international level and are a partner in the following networks:
Category 1 member of Enpr-EMA (EuroEuropean Network of Paediatric Research at the European Medicines Agency, visit website)
PedCRIN (Paediatric Clinical Research Infrastructure Network, visit website). Project period: 1.1.2017 - 30.6.2021
C4C (Connect 4 Children, visit website). Project period: 1.5.2018 - 30.4.2024
This expertise, unique in Austria in the field of research into the safety and efficacy of medicinal products in children and adolescents, is made available by us, as a qualified national hub, to both academic studies and studies conducted by the pharmaceutical industry.
This board, in an advisory capacity, assists the executive director. The task of the advisory board is to support the executive management of OKIDS GmbH with regard to specific decisions and the determination of strategic orientation concepts. The board comprises 13 members from organisations including the following:
ÖGKJ, Pharmig, Coordination Centres for Clinical Trials of the Universities, Austrian Federal Ministry of Labour, Social Affairs, Health and Consumer Protection, Austrian Federal Office for Safety and Health, EUPATI and Pro Rare.